This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Lung Cancer  • Pulmonary Diseases  • Pulmonary Diseases, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2009;302(6):616-618.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Data from recent phase 3 clinical trials show that for some patients with lung cancer, targeted therapies and other treatment regimens can achieve slight improvements in survival over current standards of care. But so far, the impact of such therapies on extending life or slowing disease progression has been modest, although some regimens may be less toxic to patients.

Some targeted therapies and other new treatment regimens for patients with lung cancer offer modest improvements in survival compared with current standards of care.

Researchers discussed the findings at the recent 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), in Orlando, Fla.

"Lung cancer is one of the most challenging cancers to treat, but the studies presented . . . highlight promising new targeted therapies and milder treatment regimens that improve survival," said Bruce Johnson, MD, director of the Lung Cancer Program at the Dana-Farber/Harvard Cancer Center in Boston, . . . [Full Text of this Article]

MAINTENANCE TRIALS



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?